RCKT Rocket Pharmaceuticals Inc

$RCKT I truly bilieve on the company and science. The downward spiral with the cash burn and the patient death was too much. A BO of less than 25$ is not fair. Top notch platform and facilities, danon disease iminent with all the FDA designations. It is time to shine

$RCKT Good to see the first three Danon patients clear the safety observation period without any major issues

$RCKT One thing that I really like about the company is that the cardiac story isn’t riding on one program. They’re building across Danon, PKP2 and BAG3 cardiomyopathies

$RCKT When a small-cap biotechnology company files a company-wide Change in Control (CIC) severance plan, it is a highly strategic move designed to protect the company’s drug pipeline valuation, stabilize the workforce, and facilitate a smooth sale. Just sayin

$RCKT btw Rocket still has other outstanding warrants that are not RCKTW and have longer (or no fixed) expiries. From the June 30, 2026 summary: • $57.11 exercise price — expire Dec 21, 2030 (~603k) • $33.63 — expire Aug 9, 2031 (~301k) • $22.51 — expire Dec 17, 2031 (two tranches totaling ~306k) • $0.01 pre-funded warrants — no expiration (~3.5M total from 2023/2024 issuances to RTW-affiliated funds). The expiry today of the Renovacor warrants corresponded to 760,086 shares of Rocket Pharmaceuticals common stock (at$65.23 ex). Hopefully no one here was suckered in to buy them only to find they just expired. Let's hope this housekeeping continues - like the Employee equity change-of-control filing last week, it all points to nice clean books that are acquisition-ready.

$RCKT RCKT short interest keeps moving in the right direction — down to 14.4M shares, from 21.9M in mid-June. That’s roughly a 34% drop in just two months. Less short pressure + a strong catalyst could make the next move in RCKT very interesting. 🚀

$RCKT I'd like to get the symbol in front of their name officially changed. 🚀 Would be more fitting. It's always interesting to me there are so few retail here but I kind of like the quiet.

$RCKT All the action today on RCKTW warrants was because they expired at the close of trade. Per the filing and halt after hours, Nasdaq has now struck them from listing and registration.

$RCKT A SHORT SQUEEZE IS COMING! THE CHARTS SCREAM IT. WITH 15% SHORT INTEREST AND BUYING PRESSURE, THIS THING IS A PRESSURE COOKER WAITING TO BURST. QUESTION IS, WHETHER THE MARKET MAKERS/INSTITUTE OWNERS ARE GOING TO LET IT RUN PASSED THE RECENT ATH'S... WILL THEY LET THIS RIP TO $30-$50 OR JUST GO TO $7 AND DUMP..... A COMPANY WITH NEW DEBTS, TONS OF CASH, FDA APPROVED DRUG FOR RARE DISEASE AND LOTS MORE IN THE PIPELINE... IT'S 300-500% UNDER PRICED AS IT IS.

$RCKT Correct me if im wrong here..... But sure looks like a bull flag pressure cooker about to explode to me, the wedge is getting tighter. As long as the shorts keep shorting, the buying pressure applies and creates even more pressure, until the 95% instit owners finally let it go. If this thing has 25% short interest by that time, we sould see a huge short squeeze event if all the planets align correctly. Id be good with $50, anymore than that is a bonus.

$RCKT RCKT is 95% institutionally owned....... Market doesn't care what the average people think... When ever the 95% decide they want this to run, it'll run, until then nothing matters, not even news or results. True Story.

$RCKT There was one slide on the RTW Biotech Opportunites Ltd's Results presentation this morning that gave a very prominent position to Rocket. The slide about how they create companies. I thought this was quite noticeable. Compared to the other companies they showed on the same slide which have generated huge value for them, Rocket looked rather good. I took it that despite the huge drop in Rocket's share price from recent years, they are becoming more proud of it: which I take as a sign that they can see value realisation coming.

$RCKT its only a matter of time before this thing is back at the val it deserves, lets HOP ON THE #ROCKET AND FLY🚀🤠

$RCKT the market still has not properly understood how important the recent safety update was of those three new patients. As people realize how extremely important that update was, the stock will run.

$RCKT I would like to see this stock fall down to the $2.25 level in order to somewhat de-risk the stock.

$RCKT RP-A501 (Danon disease) — pivotal Phase 2 dosing resumed in 2026 after a partial hold; initial 3 patients cleared the safety observation period (no TMA/capillary leak) as of Aug 2026. Rocket is negotiating with FDA on a faster path to complete the pivotal trial — a broader program update is expected 2H 2026. This is the single biggest binary catalyst. • RP-A601 (PKP2-ACM) — regulatory update on pivotal study design expected 2H 2026.

$RCKT biggest thing for me is the Danon program and what the FDA says about moving forward with more patients

$RCKT The latest Danon safety update was encouraging. All three initial patients cleared the observation period without the major safety issues they were watching for

$RCKT bearish take: FDA alignment is positive, but 9 patients still need to be treated under the new protocol, with dosing only expected to finish around mid-2027. The primary assessment is at 12 months → full pivotal readout could therefore be around mid-2028. So the FDA de-risked the path, but the key efficacy catalyst remains ~2 years away.

$RCKT Oh no, my shorts are getting crushed! Don't take it any higher, I can't take it anymore. I'm so scared this is going to be over $4 soon. No! What will I do?????